Dry Age-Related Macular Degeneration (AMD) is a degenerative condition of the center of the retina and can affect the vision in different ways.

Your symptoms may be mild, or you may have no symptoms for several years. If your dry AMD progresses, your ability to see clearly may change.

Dry AMD can cause retinal cells to deteriorate and may result in cellular death, leading to geographic atrophy and permanent vision loss.

Valeda uses photobiomodulation (PBM), specific wavelengths of light in yellow (590 nm), red (660 nm) and near-infrared (850 nm) range in a specific pattern, to stimulate energy production within the cells resulting in improved cellular health. The treatment is noninvasive and performed within 10-15 minutes in the office. Nine treatment sessions over a period of 3-5 weeks are recommended. This course is then repeated three times per year for two years.

The Valeda Light Delivery System is intended to provide improved visual acuity in patients with best corrected visual acuity of 20/32 through 20/70 and who have dry age-related macular degeneration (AMD) characterized by:

– The presence of at least 3 medium drusen {> 63 μm and ≤ 125 μm in diameter), or large drusen {> 125 μm in diameter), or non-central geographic atrophy, AND

– The absence of neovascular maculopathy or center-involving geographic atrophy

After about two years, the Valeda Light Delivery System treatment provides improved mean visual acuity of approximately one line of visual acuity (ETDRS) compared to those not receiving the treatment.

Treatment with Valeda can improve your vision now and in the future. Don’t delay. Ask your eye doctor if Valeda is right for you.